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Inhibiting ROR1 expression in Androgen-Independent Prostate Cancer Reduces 
Aggressive Cancer Phenotypes by modulation of AKT-GSK3ꞵ Pathway
Prostate cancer is a disease that has a high prevalence and mortality
amongst men. The severity of the cancer is stratified by risk, which is
based on the Gleason grade, prostate-specific antigen (PSA) level,
and clinical staging. Unlike breast cancer which can be classified into
subtypes based on molecular heterogeneity, prostate cancer has no
such classification and is treated with observation, prostatectomy, or
radiation if local, and non-specific chemotherapy and androgen
deprivation therapy (ADT) if metastatic. It is of the utmost importance
to investigate molecular targets that can specifically eradicate
prostate cancer while retaining the functions of normal tissue.
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a receptor
that is highly expressed in embryogenesis and cancer, while being
minimally expressed in normal, developed tissue. In particular,
prostate cancer exhibits moderate to high levels of ROR1 expression.
Previous research has been performed on ROR1 expression in various
cancers and its role in promoting cancerous phenotypes. The goal of
this study is to elucidate the role of ROR1 in aggressive prostate
cancer in order to validate ROR1 as a potential chemotherapeutic
target and as a predictor of aggressive prostate cancer. We
hypothesize that knocking down ROR1 can reduce the anti-apoptotic
and migratory potential of prostate cancer. Preliminary results
indicate that knocking down ROR1 reduces the phosphorylation of
AKT and GSK3ꞵ, which should lead to reduction in survival, migration,
and cell cycle progression. Furthermore, knocking down ROR1
decreased expression of anti-apoptotic p-Bad and pro-migratory
Twist1 proteins downstream of ROR1. These preliminary results
indicate that ROR1 could be a novel molecular target that can be
utilized for subtyping and treating prostate cancer.
Fig 1. ROR1 mRNA expression. ROR1 mRNA expression levels in various cell lines as
obtained and analyzed from GSE19426. A) ROR1 mRNA expression of cells in 2D
monolayer culture. No statistically significant differences in ROR1 expression between
cells (student’s T test). B) ROR1 mRNA expression of cells cultured in migration inducing
3D Matrigel. Student’s T test performed. **= p<.01 ; *** = p<0.001
Figure 1: ROR1 expression is heightened in highly metastatic prostate cancer
cell lines such as PC3. RWPE is an immortal cell line, which may explain the
heightened ROR1 expression levels in comparison to moderately aggressive
LNCaP. The increase in ROR1 expression may contribute to a more
aggressive phenotype as observed in PC3 via increased activity of the AKT
and GSK3ꞵ pathway.
Figure 2: Proteins downstream of the ROR1 pathway were probed to confirm
that knockdown of ROR1 affects phosphorylation of AKT and GSK3ꞵ . With
ROR1 knockdown, there was a reduction in AKT and GSK phosphorylation.
ROR1 activation normally leads to the phosphorylation of AKT and GSK3β.
Reduction in AKT and GSK3β phosphorylation indicates knockdown
inhibition of ROR1, a key modulator of this crucial cancer signaling cascade.
Figure 3: ROR1 knockdown reduced levels of p-Bad. Normally, ROR1
activation phosphorylates AKT. An active p-AKT will inhibit Bad by
phosphorylating it. Phosphorylated Bad will not form a heterodimer with
Bcl-2 and Bcl-xL which allow the proteins to inhibit Bax/Bak induced release
of Cytochrome C from the mitochondria. Overall, this would inhibit
apoptosis and promote cell survival. ROR1 knockdown prevents Bad from
becoming phosphorylated. Hence, dephosphorylated (active) Bad will form
a heterodimer with Bcl-2 and Bcl-xL and inhibit the proteins, enabling
Bax/Bak induced release of cytochrome C. ROR1 knockdown may activate
the apoptotic protein signaling cascade.
Figure 4: Knockdown of ROR1 decreases protein expression of Twist1, a
transcription factor known to promote migration of cells.
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• Perform Western blotting of the AKT-GSK pathway after transfecting RWPE
with shROR1
• Perform further Western blots on all cell lines to assess more downstream
apoptosis proteins and Epithelial-to-Mesenchymal (EMT) proteins.
• Perform a wound healing assay with PC3 and RWPE cells after shROR1
transfection.
• Perform apoptosis assays on all cell lines after shROR1 transfection.
• Assess ROR1 downstream proteins, migratory capacity, and apoptosis
pathway after transfecting cell lines with ROR1 overexpressing plasmid.
Future DirectionsFig 2. Western blot. Western blot on PC3 protein lysate assessing AKT and
GSK3ꞵ protein expression and AKT and GSK3ꞵ phosphorylation at serine
473 and serine 9, respectively. N=1.
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Fig 3. Western blot. Western blot on PC3 protein lysate assessing the apoptosis
protein Bad downstream AKT. N=1.
• ROR1 expression levels: GEO DataSets from NCBI have an abundance 
of RNA sequencing data. Data from GSE19426 was downloaded and 
processed via Python programming language. Expression levels of 
ROR1 were quantified for RWPE, LNCaP (androgen dependent), PC3 
(androgen independent), and a highly metastatic variant of PC3, PC3m 
by averaging the biological replicates and every probe that was used 
to obtain ROR1 expression levels.
• Western blot: PC3 cells were transfected with shROR1 plasmid and 
lipofectamine control using the lipofectamine 3000 kit. Cells 
underwent protein extraction 3 days post-transfection and were 
assessed for AKT- GSK3ꞵ proteins, apoptosis proteins, and Epithelial-
to-Mesenchymal  Transition (EMT) proteins. Band levels were 
quantified by normalizing band intensity to GAPDH using ImageJ.
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Fig 4. Western blot. Western blot on PC3 protein lysate assessing pro-
migration transcription factor Twist1. N=1.
